HRT Modestly Increases Breast Cancer Risk, Primarily with Combined Estrogen-Progestogen Therapy
The absolute increase in breast cancer risk from HRT is modest: approximately 8 additional invasive breast cancers per 10,000 women per year for combined estrogen-progestogen therapy, based on the Women's Health Initiative data 1. This translates to an 8 in 10,000 (0.08%) annual absolute risk increase.
Quantifying the Risk by HRT Type
Combined Estrogen-Progestogen Therapy (E+P)
- Hazard ratio: 1.26-2.00 depending on the study and specific formulation 2, 3
- Absolute risk: 8-36 additional cases per 10,000 women-years for recent users 3
- The WHI trial reported HR 1.26 (95% CI 1.00-1.59), which barely reached statistical significance 2
- Risk increases substantially with duration: HR reaches 1.72 for ≥5 years of use 4
- The risk is highest with norethisterone (HR 1.88) and lowest with dydrogesterone (HR 1.24) among progestogens 3
Estrogen-Only Therapy
- No increased risk or potentially protective effect 2
- WHI estrogen-only arm showed HR 0.77 (95% CI 0.59-1.01), suggesting possible risk reduction 2
- Absolute risk: 3-8 additional cases per 10,000 women-years in recent users 3
- Adjusted HR 1.15 for long-term use (≥5 years) 3
Duration Matters Critically
The breast cancer risk escalates with treatment duration:
Risk increases by 25% with every 10 prescriptions of oral opposed estrogen 5.
Critical Nuances in Risk Assessment
The Risk Disappears After Stopping
A crucial finding across multiple studies: past users of HRT show no increased breast cancer risk 1-5 years after discontinuation 2. This suggests HRT promotes existing disease rather than initiating new cancers 2.
However, past long-term use of estrogen-progestogen maintains elevated risk (HR 1.16) even after stopping 3.
Route of Administration
- Oral opposed estrogens: HR 1.38 5
- Transdermal opposed estrogens: HR 1.08 (not statistically significant) 5
- Transdermal estrogen-only: HR 1.24 6
Age and Timing Considerations
The WHI study enrolled women with average age 63 years, well past menopause onset 7. Women without previous HRT exposure showed no increased breast cancer risk when adjusted for prior use 2. This age-related finding suggests timing of initiation matters, though definitive data for younger perimenopausal women remain limited 7.
Putting Numbers in Clinical Context
For 10,000 women taking estrogen-progestogen for 1 year 1:
- 8 additional invasive breast cancers
- 7 additional CHD events
- 8 additional strokes
- 8 additional pulmonary emboli
- BUT 6 fewer colorectal cancers
- AND 5 fewer hip fractures
For 10 years of HRT use 6:
- Estrogen-only: 5 additional breast cancers per 1,000 users
- Estrogen-progestogen: 19 additional breast cancers per 1,000 users
Common Pitfalls to Avoid
Overestimating relative risk while ignoring absolute risk: A hazard ratio of 1.26 sounds alarming but represents only 8 additional cases per 10,000 women annually 1.
Assuming all HRT formulations carry equal risk: Estrogen-only therapy has a fundamentally different risk profile than combined therapy 2, 3.
Ignoring the disappearance of risk after cessation: The rapid decline in risk after stopping suggests detection bias and promotion of pre-existing disease rather than true carcinogenesis 2.
Failing to update HRT status during follow-up: Studies that don't update exposure status underestimate excess risk by up to 53% 8.
Not considering individual risk factors: Women who are leaner or have dense breasts show higher HRT-related breast cancer risk 4.
Evidence Quality Considerations
The most robust data come from the WHI randomized controlled trial, though it studied primarily older women (average age 63) using specific formulations (conjugated equine estrogen with medroxyprogesterone acetate) 1, 7. The confidence interval for the WHI breast cancer finding (0.83-1.92) included 1.0, indicating the result did not reach true statistical significance 2.
More recent observational studies from the UK 3 and Korea 4, 9 provide larger sample sizes and examine diverse formulations, consistently showing increased risk primarily with combined therapy and duration-dependent effects.
The 2022 guideline for BRCA carriers notes that short-term HRT following surgical menopause has not shown increased breast cancer risk in high-risk women up to age 51 10, suggesting context-specific risk profiles.